Targeting signaling pathways in lung cancer therapy

Bibliography

• Cho WC. Targeting the signaling pathways in cancer therapy. Expert Opin Ther Targets 2012;16:1-3
   PubMed Web of Science ®Google Scholar
• Jia Y, Yang Y, Brock MV, Epigenetic regulation of DACT2, a key component of the Wnt signaling pathway in human lung cancer. J Pathol 2012; doi:10.1002/path.4073
   Google Scholar
• Yang L, Chen Y, Cui T, Desmoplakin acts as a tumour suppressor by inhibition of the Wnt/beta-catenin signalling pathway in human lung cancer. Carcinogenesis 2012; doi:10.1093/carcin/bgs226
   Google Scholar
• Lee JS, Hur MW, Lee SK, A novel sLRP6E1E2 inhibits canonical Wnt signaling, epithelial-to-mesenchymal transition, and induces mitochondria-dependent apoptosis in lung cancer. PLoS One 2012;7(5):e36520
   Google Scholar
• Wang Y, Qiu Q, Shen JJ, Cardiac glycosides induce autophagy in human non-small cell lung cancer cells through regulation of dual signaling pathways. Int J Biochem Cell Biol 2012;44:1813-24
   PubMed Web of Science ®Google Scholar
• Tarhini A, Kotsakis A, Gooding W, Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 2010;16:5900-7
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Harvey RD, Saba N, Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer 2010;116:3903-9
   PubMed Web of Science ®Google Scholar
• Altorki N, Lane ME, Bauer T, Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 2010;28:3131-7
   PubMed Web of Science ®Google Scholar
• Nikolinakos PG, Altorki N, Yankelevitz D, Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 2010;70:2171-9
   PubMed Web of Science ®Google Scholar
• Lee JS, Hirsh V, Park K, Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012;30:1114-21
   PubMed Web of Science ®Google Scholar
• Hanrahan EO, Lin HY, Kim ES, Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010;28:193-201
   PubMed Web of Science ®Google Scholar
• Dahlberg SE, Sandler AB, Brahmer JR, Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010;28:949-54
   PubMed Web of Science ®Google Scholar
• Herbst RS, Ansari R, Bustin F, Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011;377:1846-54
   PubMed Web of Science ®Google Scholar
• Yang JC, Shih JY, Su WC, Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012;13:539-48
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Blackhall F, Krzakowski M, Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012; doi:10.1200/JCO.2011.40.9433
   Google Scholar
• Zhou C, Wu YL, Chen G, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42
   PubMed Web of Science ®Google Scholar
• Gridelli C, Ciardiello F, Gallo C, First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol 2012;20:3002-11
   Google Scholar
• Ciuleanu T, Stelmakh L, Cicenas S, Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012;13:300-8
   PubMed Web of Science ®Google Scholar
• Zhang L, Ma S, Song X, Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol 2012;13:466-75
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, von Pawel J, EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012;13:33-42
   PubMed Web of Science ®Google Scholar
• Wu K, House L, Liu W, Personalized targeted therapy for lung cancer. Int J Mol Sci 2012;13:11471-96
   Google Scholar
• Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011;10:671-84
   PubMed Web of Science ®Google Scholar
• Zhang WC, Shyh-Chang N, Yang H, Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 2012;148:259-72
   PubMed Web of Science ®Google Scholar